Our study represents a first attempt to investigate the clinical impact in TNBC of two known PD-L1 polymorphisms which have attracted much interest recently, due to their implication in expressional regulation of PD-L1, a molecule that according to mounting evidence is in the core not only of certain cancer-related events but also of clinical management of several cancer types, including TNBC. The gene discussed is CD274; the disease is cancer.